Correspondence 0001493152-22-035224 from Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Aridis Pharmaceuticals, Inc. (ARDS) (CIK 0001614067)
Date: Dec. 12, 2022 · CIK: 0001614067 · Accession: 0001493152-22-035224
AI Filing Summary & Sentiment
File numbers found in text: 333-268701
Letter
Aridis Pharmaceuticals, Inc.
University Avenue, Bldg. B
Los Gatos, CA 95032
December 12, 2022
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Jimmy McNamara
Re: Aridis Pharmaceuticals, Inc. Registration Statement on Form S-1
File No. 333-268701
Filed December 7, 2022
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Aridis Pharmaceuticals, Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, December 14, 2022, or as soon thereafter as possible. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Please notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as to the time the Registration Statement has been declared effective pursuant to this acceleration request.
[Signature page follows]
Very
truly yours,
ARIDIS
PHARMACEUTICALS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Aridis
Pharmaceuticals, Inc.
983
University Avenue, Bldg. B
Los
Gatos, CA 95032
December
12, 2022
VIA
EDGAR
United
States Securities and Exchange Commission
Division
of Corporation Finance
100 F Street, N.E.
Washington,
D.C. 20549
Attention:
Jimmy McNamara
Re: Aridis
Pharmaceuticals, Inc.
Registration Statement on Form S-1
File
No. 333-268701
Filed
December 7, 2022
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the “Act”), Aridis Pharmaceuticals,
Inc. (the “Company”) respectfully requests that the effective date of the registration statement referred to above be accelerated
so that it will become effective at 4:30 p.m., Eastern Time, on Wednesday, December 14, 2022, or as soon thereafter as possible. In
making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
Please
notify Jeffrey Fessler of Sheppard Mullin Richter & Hampton LLP, counsel to the Company, at (212) 634-3067 as soon as possible as
to the time the Registration Statement has been declared effective pursuant to this acceleration request.
[Signature
page follows]
Very
truly yours,
ARIDIS
PHARMACEUTICALS, INC.
By:
/s/
Vu Truong
Name:
Vu
Truong
Title:
CEO
cc:
Jeffrey Fessler, Sheppard Mullin Richter & Hampton LLP